Cervical ganglion block attenuates the progression of pulmonary hypertension via nitric oxide and arginase pathways

Hypertension

Volumn 63, Issue 2, 2014, Pages 309-315

  Na, Sungwon ^a   Kim, Ok Soo ^a   Ryoo, Sungwoo ^b   Kweon, Tae Dong ^a   Choi, Yong Seon ^a   Shim, Hyo Sup ^a   Oh, Young Jun ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Kangwon National University   (South Korea)

Author keywords

autonomic pathways; hypertension; nitric oxide; pulmonary; sympathetic nervous system

Indexed keywords

ARGINASE; ARGINASE 1; ARGINASE 2; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MONOCROTALINE; NITRIC OXIDE; NITRITE; ROPIVACAINE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY; ARTICLE; CERVICAL GANGLION BLOCK; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HEART LEFT VENTRICLE MASS; HEART RATE VARIABILITY; HEART RIGHT VENTRICLE PRESSURE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MICROSCOPY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; SUPERIOR CERVICAL GANGLION; SYMPATHETIC BLOCKING; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT;

EID: 84892915030     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.01979     Document Type: Article

References (42)

1. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol. 2008;51:1527-1538.
2. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S43-S54.
3. Förstermann U, Münzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006;113:1708-1714.
4. Ou ZJ, Wei W, Huang DD, Luo W, Luo D, Wang ZP, Zhang X, Ou JS. L-arginine restores endothelial nitric oxide synthase-coupled activity and attenuates monocrotaline-induced pulmonary artery hypertension in rats. Am J Physiol Endocrinol Metab. 2010;298:E1131-E1139.
5. Sasaki A, Doi S, Mizutani S, Azuma H. Roles of accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, and attenuated nitric oxide synthase activity in endothelial cells for pulmonary hypertension in rats. Am J Physiol Lung Cell Mol Physiol. 2007;292:L1480-L1487.
6. Gryglewski RJ, Botting RM, Vane JR. Mediators produced by the endothelial cell. Hypertension. 1988;12:530-548.
7. Levine AB, Punihaole D, Levine TB. Characterization of the role of nitric oxide and its clinical applications. Cardiology. 2012;122:55-68.
8. Maarsingh H, Pera T, Meurs H. Arginase and pulmonary diseases. Naunyn Schmiedebergs Arch Pharmacol. 2008;378:171-184.
9. Morris SM Jr. Recent advances in arginine metabolism: roles and regulation of the arginases. Br J Pharmacol. 2009;157:922-930.
10. Salvi SS. Alpha1-adrenergic hypothesis for pulmonary hypertension. Chest. 1999;115:1708-1719.
11. Nootens M, Kaufmann E, Rector T, Toher C, Judd D, Francis GS, Rich S. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol. 1995;26:1581-1585.
12. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P. Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation. 2004;110:1308-1312.
13. Ciarka A, Doan V, Velez-Roa S, Naeije R, van de Borne P. Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010;181:1269-1275.
14. Wensel R, Jilek C, Dörr M, Francis DP, Stadler H, Lange T, Blumberg F, Opitz C, Pfeifer M, Ewert R. Impaired cardiac autonomic control relates to disease severity in pulmonary hypertension. Eur Respir J. 2009;34:895-901.
15. Harris KF, Matthews KA. Interactions between autonomic nervous system activity and endothelial function: a model for the development of cardiovascular disease. Psychosom Med. 2004;66:153-164.
16. Burnstock G, Ralevic V. New insights into the local regulation of blood flow by perivascular nerves and endothelium. Br J Plast Surg. 1994;47:527-543.
17. Blomberg S, Emanuelsson H, Kvist H, Lamm C, Pontén J, Waagstein F, Ricksten SE. Effects of thoracic epidural anesthesia on coronary arteries and arterioles in patients with coronary artery disease. Anesthesiology. 1990;73: 840-847.
18. Manolis AJ, Olympios C, Sifaki M, Handanis S, Bresnahan M, Gavras I, Gavras H. Suppressing sympathetic activation in congestive heart failure. A new therapeutic strategy. Hypertension. 1995;26:719-724.
19. Foss JD, Fink GD, Osborn JW. Reversal of genetic salt-sensitive hypertension by targeted sympathetic ablation. Hypertension. 2013;61:806-811.
20. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol. 2011;8:443-455.
21. Faber JE, Szymeczek CL, Salvi SS, Zhang H. Enhanced alpha1-adrenergic trophic activity in pulmonary artery of hypoxic pulmonary hypertensive rats. Am J Physiol Heart Circ Physiol. 2006;291:H2272-H2281.
22. Matori H, Umar S, Nadadur RD, Sharma S, Partow-Navid R, Afkhami M, Amjedi M, Eghbali M. Genistein, a soy phytoestrogen, reverses severe pulmonary hypertension and prevents right heart failure in rats. Hypertension. 2012;60:425-430.
23. Kobayashi H, Hataishi R, Mitsufuji H, Tanaka M, Jacobson M, Tomita T, Zapol WM, Jones RC. Antiinflammatory properties of inducible nitric oxide synthase in acute hyperoxic lung injury. Am J Respir Cell Mol Biol. 2001;24:390-397.
24. Granger DN, Kubes P. Nitric oxide as antiinflammatory agent. Methods Enzymol. 1996;269:434-442.
25. Dawson TA, Li D, Woodward T, Barber Z, Wang L, Paterson DJ. Cardiac cholinergic NO-cGMP signaling following acute myocardial infarction and nNOS gene transfer. Am J Physiol Heart Circ Physiol. 2008;295:H990-H998.
26. Li D, Nikiforova N, Lu CJ, Wannop K, McMenamin M, Lee CW, Buckler KJ, Paterson DJ. Targeted neuronal nitric oxide synthase transgene delivery into stellate neurons reverses impaired intracellular calcium transients in prehypertensive rats. Hypertension. 2013;61:202-207.
27. Lipov EG, Joshi JR, Sanders S, Wilcox K, Lipov S, Xie H, Maganini R, Slavin K. Effects of stellate-ganglion block on hot flushes and night awakenings in survivors of breast cancer: a pilot study. Lancet Oncol. 2008;9:523-532.
28. Chester M, Hammond C, Leach A. Long-term benefits of stellate ganglion block in severe chronic refractory angina. Pain. 2000;87:103-105.
29. Schürmann M, Gradl G, Wizgal I, Tutic M, Moser C, Azad S, Beyer A. Clinical and physiologic evaluation of stellate ganglion blockade for complex regional pain syndrome type I. Clin J Pain. 2001;17:94-100.
30. Liang F, Yang S, Yao L, Belardinelli L, Shryock J. Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries. Hypertension. 2012;59:705-711.
31. Sanyal SN, Ono K. Derangement of autonomic nerve control in rat with right ventricular failure. Pathophysiology. 2002;8:197-203.
32. Reed AS, Tschakovsky ME, Minson CT, Halliwill JR, Torp KD, Nauss LA, Joyner MJ. Skeletal muscle vasodilatation during sympathoexcitation is not neurally mediated in humans. J Physiol. 2000;525(Pt 1):253-262.
33. Kamezaki F, Tasaki H, Yamashita K, Tsutsui M, Koide S, Nakata S, Tanimoto A, Okazaki M, Sasaguri Y, Adachi T, Otsuji Y. Gene transfer of extracellular superoxide dismutase ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med. 2008;177:219-226.
34. Rashid M, Kotwani A, Fahim M. Long-acting phosphodiesterase 5 inhibitor, tadalafil, and superoxide dismutase mimetic, tempol, protect against acute hypoxia-induced pulmonary hypertension in rats. Hum Exp Toxicol. 2012;31:626-636.
35. Campese VM, Shaohua Y, Huiquin Z. Oxidative stress mediates angiotensin II-dependent stimulation of sympathetic nerve activity. Hypertension. 2005;46:533-539.
36. Miura H, Morgan DA, Gutterman DD. Oxygen-derived free radicals contribute to neural stunning in the canine heart. Am J Physiol. 1997;273(3 Pt 2):H1569-H1575.
37. Kobayashi M, Massiello A, Karimov JH, Van Wagoner DR, Fukamachi K. Cardiac autonomic nerve stimulation in the treatment of heart failure. Ann Thorac Surg. 2013;96:339-345.
38. Ronkainen E, Korpelainen JT, Heikkinen E, Myllylä VV, Huikuri HV, Isojärvi JI. Cardiac autonomic control in patients with refractory epilepsy before and during vagus nerve stimulation treatment: a one-year followup study. Epilepsia. 2006;47:556-562.
39. Olshansky B, Sabbah HN, Hauptman PJ, Colucci WS. Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation. 2008;118:863-871.
40. Lewis ME, Al-Khalidi AH, Bonser RS, Clutton-Brock T, Morton D, Paterson D, Townend JN, Coote JH. Vagus nerve stimulation decreases left ventricular contractility in vivo in the human and pig heart. J Physiol. 2001;534(Pt. 2):547-552.
41. Zhang Y, Popovic ZB, Bibevski S, Fakhry I, Sica DA, Van Wagoner DR, Mazgalev TN. Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. Circ Heart Fail. 2009;2:692-699.
42. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol. 2009;297:L1013-L1032.